FDA.reportPublic FDA data

cedazuridine 100 MG / decitabine 35 MG Oral Tablet

RxCUI
2384457
RxNorm name
cedazuridine 100 MG / decitabine 35 MG Oral Tablet
Display name
cedazuridine 100 MG / decitabine 35 MG Oral Tablet
Full name
cedazuridine 100 MG / decitabine 35 MG Oral Tablet
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:08

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
INQOVICEDAZURIDINE AND DECITABINETaiho Pharmaceutical Co., Ltd.91a0f80b-f865-4d06-a40d-4d148d99ee712026-05-25Warnings, Adverse reactionsExact identifier
rxcui: 2384457

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
91a0f80b-f865-4d06-a40d-4d148d99ee71cedazuridine 100 MG / decitabine 35 MG Oral Tablet [PSN] · cedazuridine 100 MG / decitabine 35 MG Oral Tablet [SCD]213These highlights do not include all the information needed to use INQOVI safely and effectively. See full prescribing information for INQOVI. INQOVI ® (decitabine and cedazuridine) tablets, for oral use Initial U.S. Approval: 202020260525